← 返回

双重 mRNA 共递送用于原位生成吞噬增强型 CAR 巨噬细胞增强肝细胞癌免疫治疗

英文原题:Dual mRNA co-delivery for in situ generation of phagocytosis-enhanced CAR macrophages augments hepatocellular carcinoma immunotherapy.

查看英文原题

Dual mRNA co-delivery for in situ generation of phagocytosis-enhanced CAR macrophages augments hepatocellular carcinoma immunotherapy.

PubMed 2023/07/19(内容时间) J Control Release Q1 · IF 12.4(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

肝细胞癌(HCC)是一种常见且致命的疾病,由于有效疗法有限,晚期HCC患者很少出现肿瘤消退。鉴于HCC中巨噬细胞的富集及其在肿瘤免疫中的作用,将其转化为嵌合抗原受体巨噬细胞(CAR-Ms)被认为可增强针对HCC细胞的吞噬作用和杀瘤免疫。为验证这一假设,将编码CAR的mRNA包裹在靶向肝脏巨噬细胞的脂质纳米颗粒(LNP)中。

值得注意的是,这些LNP吸附特定的血浆蛋白,使其能够靶向HCC相关巨噬细胞。此外,编码缺乏ITIMs的Siglec-G(Siglec-GΔITIMs)的mRNA通过LNP共递送至肝脏巨噬细胞,以解除CD24介导的CAR-Ms免疫抑制。在HCC小鼠模型中,用产生CAR-Ms的LNP以及CD24-Siglec-G阻断治疗的小鼠显著提高了肝脏巨噬细胞的吞噬功能,减少了肿瘤负荷并延长了生存时间。可以说,我们的工作为HCC的治疗提出了一种有效且灵活的策略,值得在临床试验中进一步严格评估。

展开英文摘要原文

Hepatocellular carcinoma (HCC) is a prevalent and lethal disease, and tumor regression rarely occurs in advanced HCC patients due to limited effective therapies. Given the enrichment of macrophages in HCC and their role in tumor immunity, transforming them into chimeric antigen receptor macrophages (CAR-Ms) is thought to increase HCC cell-directed phagocytosis and tumoricidal immunity. To test this hypothesis, mRNA encoding CAR is encapsulated in a lipid nanoparticle (LNP) that targets liver macrophages.

Notably, the LNPs adsorb specific plasma proteins that enable them to target HCC-associated macrophages.

Moreover, mRNA encoding Siglec-G lacking ITIMs (Siglec-GΔITIMs) is codelivered to liver macrophages by LNP to relieve CD24-mediated CAR-Ms immune suppression. Mice treated with LNPs generating CAR-Ms as well as CD24-Siglec-G blockade significantly elevate the phagocytic function of liver macrophages, reduce tumor burden and increase survival time in an HCC mouse model. Arguably, our work suggests an efficacious and flexible strategy for the treatment of HCC and warrants further rigorous evaluation in clinical trials.

论文信息

作者
Yang Z、Liu Y、Zhao K、Jing W、Gao L、Dong X、Wang Y、Han M
第一作者单位
NMPA Key Laboratory for Technology Research and Evaluation of Drug Products and Key Laboratory of Chemical Biology (Ministry of Education), Department of Pharmaceutics, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, 44 Cultural West Road, Shandong Province 250012, China.China
通讯作者单位
NMPA Key Laboratory for Technology Research and Evaluation of Drug Products and Key Laboratory of Chemical Biology (Ministry of Education), Department of Pharmaceutics, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, 44 Cultural West Road, Shandong Province 250012, China. Electronic address: xinyijiang@sdu.edu.cn.China
文献类型
非美国政府资助研究
期刊
Journal of controlled release : official journal of the Controlled Release Society2023 Aug
原文标识
PubMed 37451547 · DOI 10.1016/j.jconrel.2023.07.021